Print

ArQule, Inc. (ARQL) Release: Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer Presented at American Society of Clinical Oncology 2013  
6/3/2013 7:09:37 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ArQule, Inc. (Nasdaq: ARQL) today announced final data from a randomized, placebo-controlled, double-blind, Phase 2 clinical trial with tivantinib in combination with cetuximab and irinotecan in patients with relapsed or refractory KRAS wild-type metastatic colorectal cancer (CRC). These data were presented today at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) (abstract number 3508) by Dr. Cathy Eng, M.D., F.A.C.P., M.D. Anderson Cancer Center, Associate Director, Colorectal Center.

Help employers find you! Check out all the jobs and post your resume.

//-->